Market Research Logo

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018

Summary

PTSD is a mental health condition that is triggered by either experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants and cognitive therapy. There are 38 products in development for this indication.

OCD is characterized by unreasonable thoughts and fears (obsessions) that lead to repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again.

Treatment includes antidepressants and psychiatric medications. There are nine products in development for this indication.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches.

Treatment includes antidepressants, mood stabilizers and antipsychotics. There are 212 products in development for this indication.

Molecular targets acted on by products in development for depression and anxiety disorders include neurotransmitter receptors such as glutamate receptors and 5-hydroxytryptamine receptors. Companies operating in this pipeline space include NeuroRx, Amorsa Therapeutics and Johnson & Johnson.

This report “Depression and Anxiety Disorders Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for depression and anxiety disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD) and depression, and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Depression and Anxiety Disorders Report Coverage
2.2 Post-Traumatic Stress Disorder (PTSD) - Overview
2.3 Obsessive-Compulsive Disorder - Overview
2.4 Depression - Overview
3 Therapeutics Development
3.1 Post-Traumatic Stress Disorder (PTSD)
3.2 Obsessive-Compulsive Disorder
3.3 Depression
4 Therapeutics Assessment
4.1 Post-Traumatic Stress Disorder (PTSD)
4.2 Obsessive-Compulsive Disorder
4.3 Depression
5 Companies Involved in Therapeutics Development
5.1 Post-Traumatic Stress Disorder (PTSD)
5.2 Obsessive-Compulsive Disorder
5.3 Depression
6 Dormant Projects
6.1 Post-Traumatic Stress Disorder (PTSD)
6.2 Obsessive-Compulsive Disorder
6.3 Depression
7 Discontinued Products
7.1 Post-Traumatic Stress Disorder (PTSD)
7.2 Obsessive-Compulsive Disorder
7.3 Depression
8 Product Development Milestones
8.1 Post-Traumatic Stress Disorder (PTSD)
8.2 Obsessive-Compulsive Disorder
8.3 Depression
9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer
1.1 List of Tables
Table 1: Number of Products under Development for Post-Traumatic Stress Disorder (PTSD)
Table 2: Number of Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD)
Table 3: Number of Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD)
Table 4: Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD)
Table 5: Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD)
Table 6: Number of Products under Development for Obsessive-Compulsive Disorder
Table 7: Number of Products under Development by Companies, Obsessive-Compulsive Disorder
Table 8: Number of Products under Development by Universities/Institutes, Obsessive-Compulsive Disorder
Table 9: Products under Development by Companies, Obsessive-Compulsive Disorder
Table 10: Products under Development by Universities/Institutes, Obsessive-Compulsive Disorder
Table 11: Number of Products under Development for Depression
Table 12: Number of Products under Development by Companies, Depression
Table 13: Number of Products under Development by Universities/Institutes, Depression
Table 14: Products under Development by Companies, Depression
Table 15: Products under Development by Universities/Institutes, Depression
Table 16: Number of Products by Stage and Target, Post-Traumatic Stress Disorder (PTSD)
Table 17: Number of Products by Stage and Mechanism of Action, Post-Traumatic Stress Disorder (PTSD)
Table 18: Number of Products by Stage and Route of Administration, Post-Traumatic Stress Disorder (PTSD)
Table 19: Number of Products by Stage and Molecule Type, Post-Traumatic Stress Disorder (PTSD)
Table 20: Number of Products by Stage and Target, Obsessive-Compulsive Disorder
Table 21: Number of Products by Stage and Mechanism of Action, Obsessive-Compulsive Disorder
Table 22: Number of Products by Stage and Route of Administration, Obsessive-Compulsive Disorder
Table 23: Number of Products by Stage and Molecule Type, Obsessive-Compulsive Disorder
Table 24: Number of Products by Stage and Target, Depression
Table 25: Number of Products by Stage and Mechanism of Action, Depression
Table 26: Number of Products by Stage and Route of Administration, Depression
Table 27: Number of Products by Stage and Molecule Type, Depression
Table 28: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd
Table 29: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd
Table 30: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc
Table 31: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc
Table 32: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc
Table 33: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd
Table 34: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc
Table 35: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd
Table 36: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc
Table 37: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co
Table 38: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc
Table 39: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd
Table 40: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson
Table 41: Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc
Table 42: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp
Table 43: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd
Table 44: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics SAS
Table 45: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi
Table 46: Post-Traumatic Stress Disorder (PTSD) - Pipeline by SpringWorks Therapeutics LLC
Table 47: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp
Table 48: Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd
Table 49: Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc
Table 50: Obsessive-Compulsive Disorder - Pipeline by Biohaven Pharmaceutical Holding Company Ltd
Table 51: Obsessive-Compulsive Disorder - Pipeline by Omeros Corp
1.2 List of Figures
Figure 1: Number of Products under Development for Post-Traumatic Stress Disorder (PTSD)
Figure 2: Number of Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD)
Figure 3: Number of Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD)
Figure 4: Number of Products under Development for Obsessive-Compulsive Disorder
Figure 5: Number of Products under Development by Companies, Obsessive-Compulsive Disorder
Figure 6: Number of Products under Development for Depression
Figure 7: Number of Products under Development by Companies, Depression
Figure 8: Number of Products under Development by Universities/Institutes, Depression
Figure 9: Number of Products by Top 10 Targets, Post-Traumatic Stress Disorder (PTSD)
Figure 10: Number of Products by Stage and Top 10 Targets, Post-Traumatic Stress Disorder (PTSD)
Figure 11: Number of Products by Top 10 Mechanism of Actions, Post-Traumatic Stress Disorder (PTSD)
Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions, Post-Traumatic Stress Disorder (PTSD)
Figure 13: Number of Products by Routes of Administration, Post-Traumatic Stress Disorder (PTSD)
Figure 14: Number of Products by Stage and Routes of Administration, Post-Traumatic Stress Disorder (PTSD)
Figure 15: Number of Products by Molecule Types, Post-Traumatic Stress Disorder (PTSD)
Figure 16: Number of Products by Stage and Molecule Types, Post-Traumatic Stress Disorder (PTSD)
Figure 17: Number of Products by Top 10 Targets, Obsessive-Compulsive Disorder
Figure 18: Number of Products by Stage and Top 10 Targets, Obsessive-Compulsive Disorder
Figure 19: Number of Products by Top 10 Mechanism of Actions, Obsessive-Compulsive Disorder
Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, Obsessive-Compulsive Disorder
Figure 21: Number of Products by Stage and Routes of Administration, Obsessive-Compulsive Disorder
Figure 22: Number of Products by Stage and Top 10 Molecule Types, Obsessive-Compulsive Disorder
Figure 23: Number of Products by Top 10 Targets, Depression
Figure 24: Number of Products by Stage and Top 10 Targets, Depression
Figure 25: Number of Products by Top 10 Mechanism of Actions, Depression
Figure 26: Number of Products by Stage and Top 10 Mechanism of Actions, Depression
Figure 27: Number of Products by Routes of Administration, Depression
Figure 28: Number of Products by Stage and Routes of Administration, Depression
Figure 29: Number of Products by Molecule Types, Depression
Figure 30: Number of Products by Stage and Molecule Types, Depression

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report